Raymond James Financial’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$139M Sell
2,903,988
-627,017
-18% -$26.9M 0.04% 429
2026
Q1
$130M Buy
3,531,005
+363,894
+11% +$17.2M 0.04% 412
2025
Q4
$161M Sell
3,167,111
-114,968
-4% -$5.88M 0.05% 336
2025
Q3
$182M Sell
3,282,079
-87,608
-3% -$5.13M 0.06% 293
2025
Q2
$233M Sell
3,369,687
-345,619
-9% -$23.5M 0.08% 225
2025
Q1
$258M Sell
3,715,306
-991,860
-21% -$81.9M 0.1% 192
2024
Q4
$405M Buy
+4,707,166
New +$509M 0.15% 115

Other funds holding NVO

Raymond James Financial's NVO Position: Q2 2026 in Review

Raymond James Financial reduced its Novo Nordisk (NVO) stake by 18% in Q2 2026, selling an estimated $26.9M and leaving 2,903,988 shares worth $139M. The position accounts for 0.04% of the portfolio, ranked #429.

Raymond James Financial first reported a position in NVO in Q4 2024 and has held it in 7 quarters since. The position peaked at $405M in Q4 2024. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Raymond James Financial held 2,903,988 shares of Novo Nordisk worth $139M as of Q2 2026.
  • Raymond James Financial sold 627,017 Novo Nordisk shares in Q2 2026, an estimated $26.9M.
  • Novo Nordisk made up 0.04% of Raymond James Financial's portfolio in Q2 2026, its #429 holding.
  • Raymond James Financial first reported a position in Novo Nordisk in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Novo Nordisk position peaked at $405M in Q4 2024.
  • 1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.